SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies,
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
This strategic decision will unlock significant value for our scientific and industrial products business
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
Subscribe To Our Newsletter & Stay Updated
